At FDA, the entire team that handles communications for the agency lost their jobs, according to staffers who were among those fired. And more than 800 people were fired at the FDA's Center for Drug Evaluation and Research, according to an official who was laid off and fears retribution for sharing information.
https://www.npr.org/sections/shots-health-news/2025/04/03/g-s1-58145/hhs-fda-cdc-cuts-spending
I think there is no reason to assume anything about what the job cuts will and will not affect. 20% of FDA's workforce has been cut so far, and that is likely a down payment, since much larger reductions are expected across the public service. I do think things can go either way, as I said, I just think that the more likely way is that the less contentious areas like generics are likely to simply be ignored for a while. But I certainly wouldn't be surprised if they are simply rubber stamped either.
Ann: Acrux receives $1.73m advance on FY25 R&D Tax Incentive, page-12
Add to My Watchlist
What is My Watchlist?
